サイトマップお問合わせ

  • 新規会員登録
  • ログイン

主要文献一覧表

文献概要 タイトル 著者 書誌事項
ヒト型モノクローナル抗体ベクティビックス®の製造方法 From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. Nat Biotechnol 25(10): 1134-1143, 2007.
国内臨床第II相試験 A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Muro K, Yoshino T, Doi T, Shirao K, Takiuchi H, Hamamoto Y, Watanabe H, Yang BB, Asahi D. Jpn J Clin Oncol 39(5): 321-326, 2009.
海外臨床第I相試験 Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA. Clin Cancer Res 14(2): 502-508, 2008.
海外臨床第II相試験 Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ. Cancer 110(5): 980-988, 2007.
ベクティビックス®単剤による治療 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. J Clin Oncol 25(13): 1658-1664, 2007.
ベクティビックス®単剤による治療(KRAS遺伝子に関する検討) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. J Clin Oncol 26(10): 1626-34, 2008.
ベクティビックス®単剤による治療(継続試験) Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG. Br J Cancer 97(11): 1469-1474, 2007.
ベクティビックス®の治療による皮膚障害に関する検討 Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. J Clin Oncol 28(8): 1351-1357, 2010.